NCT03516617View on ClinicalTrials.gov

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

October 16, 2030

Study Completion Date

October 16, 2030

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Patient Observation

Undergo observation

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (3)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER